Literature DB >> 17935184

Comparison of strain-specific antibody responses during primary and secondary infections with respiratory syncytial virus.

Paul D Scott1, Rachel Ochola, Charles Sande, Mwanajuma Ngama, Emelda A Okiro, Graham F Medley, D James Nokes, Patricia A Cane.   

Abstract

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in infants. RSV repeatedly reinfects individuals: this may be due in part to the variability of the attachment (G) glycoprotein and changes in this protein have been shown to be under positive selection. Infants experiencing their primary infection show a genotype-specific antibody response with respect to the variable regions of the G protein. A prospective study of RSV infections in a birth cohort in rural Kenya identified infants experiencing repeat infections with RSV. The serum antibody responses of these infants were investigated with respect to their anti-RSV reactions in an enzyme-linked immunosorbent assay (ELISA) and the specificity of the response to a variable region of the G protein by ELISA and immunoblotting using bacterially expressed polypeptides representative of the currently circulating strains of RSV. The results presented here confirm that the primary antibody response to the variable regions of the G protein is generally genotype-specific, but show that the response may become cross-reactive (at least within group A viruses) during secondary infections even where the secondary infection is of the same genotype as the initial infection. Also, some infants who did not mount a detectable antibody response to whole RSV antigens during their primary infection nevertheless showed genotype-specific responses to the G protein. In conclusion, the strain-specific nature of the serum antibody response to the variable regions of the G protein of RSV observed in primary infections can become cross-reactive in subsequent reinfections. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17935184      PMCID: PMC7612239          DOI: 10.1002/jmv.20999

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  29 in total

1.  Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains.

Authors:  C Palomo; P A Cane; J A Melero
Journal:  J Med Virol       Date:  2000-04       Impact factor: 2.327

2.  Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice.

Authors:  C A Siegrist; C Barrios; X Martinez; C Brandt; M Berney; M Córdova; J Kovarik; P H Lambert
Journal:  Eur J Immunol       Date:  1998-12       Impact factor: 5.532

3.  Evolutionary pattern of the G glycoprotein of human respiratory syncytial viruses from antigenic group B: the use of alternative termination codons and lineage diversification.

Authors:  I Mart Nez; O Vald S; A Delfraro; J Arbiza; J Russi; J A Melero
Journal:  J Gen Virol       Date:  1999-01       Impact factor: 3.891

4.  Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein.

Authors:  Kalina T Zlateva; Philippe Lemey; Elien Moës; Anne-Mieke Vandamme; Marc Van Ranst
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Molecular epidemiology of respiratory syncytial virus infections among children with acute respiratory symptoms in a community over three seasons.

Authors:  Mizuho Sato; Reiko Saito; Takatsugu Sakai; Yasuko Sano; Makoto Nishikawa; Asami Sasaki; Yugo Shobugawa; Fumitake Gejyo; Hiroshi Suzuki
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

6.  Analysis of the human serological immune response to a variable region of the attachment (G) protein of respiratory syncytial virus during primary infection.

Authors:  P A Cane; H M Thomas; A F Simpson; J E Evans; C A Hart; C R Pringle
Journal:  J Med Virol       Date:  1996-03       Impact factor: 2.327

7.  Evolution of subgroup A respiratory syncytial virus: evidence for progressive accumulation of amino acid changes in the attachment protein.

Authors:  P A Cane; C R Pringle
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  The immunologic response to infection with respiratory syncytial virus in infants.

Authors:  K McIntosh; H B Masters; I Orr; R K Chao; R M Barkin
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

9.  Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children.

Authors:  F W Henderson; A M Collier; W A Clyde; F W Denny
Journal:  N Engl J Med       Date:  1979-03-08       Impact factor: 91.245

10.  A prospective three-year cohort study of the epidemiology and virology of acute respiratory infections of children in rural India.

Authors:  Shobha Broor; Shama Parveen; Preeti Bharaj; Velisetty S Prasad; Kavalu N Srinivasulu; Krishna M Sumanth; Suresh Kumar Kapoor; Karen Fowler; Wayne M Sullender
Journal:  PLoS One       Date:  2007-06-06       Impact factor: 3.240

View more
  12 in total

1.  High frequency of repeated infections due to emerging genotypes of human respiratory syncytial viruses among children during eight successive epidemic seasons in Japan.

Authors:  Masahiro Yamaguchi; Yasuko Sano; Isolde C Dapat; Reiko Saito; Yasushi Suzuki; Akihiko Kumaki; Yugo Shobugawa; Clyde Dapat; Makoto Uchiyama; Hiroshi Suzuki
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

2.  Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein.

Authors:  Yoshihiko Murata; Paula M Lightfoote; Jamie N Biear; Ann R Falsey; Edward E Walsh
Journal:  Vaccine       Date:  2010-07-23       Impact factor: 3.641

3.  Human Respiratory Syncytial Virus Subtypes A and B Infection Among Children Attending Primary and Secondary Health Care Facilities in Ibadan, Nigeria.

Authors:  O Ogunsemowo; D O Olaleye; G N Odaibo
Journal:  Arch Basic Appl Med       Date:  2018-05-03

4.  Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.

Authors:  José A Melero; Martin L Moore
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

5.  Identifying infections with respiratory syncytial virus by using specific immunoglobulin G (IgG) and IgA enzyme-linked immunosorbent assays with oral-fluid samples.

Authors:  Emelda A Okiro; Charles Sande; Martin Mutunga; Graham F Medley; Patricia A Cane; D James Nokes
Journal:  J Clin Microbiol       Date:  2008-02-27       Impact factor: 5.948

6.  Antiviral activities of extracts from Hong Kong seaweeds.

Authors:  Hui Wang; Engchoon Vincent Ooi; Put O Ang
Journal:  J Zhejiang Univ Sci B       Date:  2008-12       Impact factor: 3.066

7.  The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease.

Authors:  E O Ohuma; E A Okiro; R Ochola; C J Sande; P A Cane; G F Medley; C Bottomley; D J Nokes
Journal:  Am J Epidemiol       Date:  2012-10-11       Impact factor: 4.897

8.  Genetic diversity of human respiratory syncytial virus circulating among children in Ibadan, Nigeria.

Authors:  Olukunle Ogunsemowo; David O Olaleye; Georgina N Odaibo
Journal:  PLoS One       Date:  2018-01-23       Impact factor: 3.240

9.  The incidence and clinical burden of respiratory syncytial virus disease identified through hospital outpatient presentations in Kenyan children.

Authors:  Emelda A Okiro; Mwanajuma Ngama; Ann Bett; D James Nokes
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

10.  Molecular epidemiology and disease severity of human respiratory syncytial virus in Vietnam.

Authors:  Dinh Nguyen Tran; Thi Minh Hong Pham; Manh Tuan Ha; Thi Thu Loan Tran; Thi Kim Huyen Dang; Lay-Myint Yoshida; Shoko Okitsu; Satoshi Hayakawa; Masashi Mizuguchi; Hiroshi Ushijima
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.